Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an announcement.
Shandong Xinhua Pharmaceutical Company Limited has announced the renewal of its trademark license agreement with Shandong Xinhua Pharmaceutical Branch of Hualu Holdings Co. Ltd. This agreement, effective from January 1, 2026, to December 31, 2028, allows the company to continue using the ‘Xinhua’ trademark. This renewal is part of a continuing connected transaction and reflects the company’s strategic focus on maintaining its brand identity and market position. The transaction is subject to reporting and review requirements under Hong Kong’s Listing Rules but is exempt from certain approval requirements, indicating a streamlined regulatory process.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a joint stock company based in China, operating in the pharmaceutical industry. The company is primarily involved in the production and distribution of pharmaceutical products and holds a significant market presence through its trademark ‘Xinhua.’
Average Trading Volume: 3,387,304
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.43B
For detailed information about 0719 stock, go to TipRanks’ Stock Analysis page.